A garage-built Alzheimer drug shows how far DIY biotech has come
Douglas Yao says PAC-832 was designed and synthesized in a garage lab, a striking marker for founder-led biotech even as the Alzheimer candidate remains preclinical and self-funded.
By Ryan Merket · Published
Primary source: X
Why it matters
PAC-832 is a founder-led attempt to revive a neglected Alzheimer mechanism with small-molecule chemistry, but the evidence is still preclinical and company-generated.
Douglas Yao (@DouglasYaoDY) published preclinical data on June 27th for PAC-832, an experimental Alzheimer disease drug candidate from Pace Pharmaceuticals that he says he designed and synthesized in a chemistry lab built in his garage. The claim is less that a garage has solved Alzheimer disease than that drug-discovery tooling has advanced to the point where a founder can push a novel CNS molecule from computational design to animal data largely outside the traditional pharmaceutical infrastructure.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.